2018
DOI: 10.1634/theoncologist.2018-0331
|View full text |Cite
|
Sign up to set email alerts
|

Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas

Abstract: Background International guidelines suggest hepatitis C virus (HCV) eradication by direct‐acting antivirals (DAAs) after first‐line immunochemotherapy (I‐CT) in patients with HCV‐positive diffuse large B‐cell lymphoma (DLBCL), although limited experiences substantiate this recommendation. Moreover, only a few data concerning concurrent administration of DAAs with I‐CT have been reported. Subjects, Materials, and Methods We analyzed hematological and virological outcome and survival of 47 consecutive patients w… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

5
51
2

Year Published

2019
2019
2021
2021

Publication Types

Select...
7
2
1

Relationship

6
4

Authors

Journals

citations
Cited by 61 publications
(58 citation statements)
references
References 34 publications
(55 reference statements)
5
51
2
Order By: Relevance
“…In December, 2017, the patient was also evaluated for HIV-1 and 2, HBV, and HCV serum markers to avoid any flare-ups of viral hepatitis during chemotherapy. Antibodies to HIV 1 and 2 were sought using a commercial enzyme-linked immunosorbent assay (ELISA) (Abbott Lab., North Chicago, Ill, USA), with positive results always confirmed by Western blot analysis (Genelabs Diagnostics, Science Park Drive, Singapore); HBsAg, total anti-HBc, and anti-hepatitis B surface antibody (HBs),and anti-HCV were tested using commercial immunoenzymatic assays (Abbott Laboratories, North Chicago, IL, USA: AxSYM® HBsAg (v2) M/S for HBsAg, AxSYM® HCV (v3) for anti-HCV, AxSYM® CORE™ (v2) for total anti-HBc, and AxSYM® AUSAB® for anti-HBs) as described in previous studies [5][6][7][8][9]. The results were HIV-1,2 negative, HCV-Ab negative, HBsAg/HBsAb negative and HBcAb positive.…”
Section: Case Reportmentioning
confidence: 99%
“…In December, 2017, the patient was also evaluated for HIV-1 and 2, HBV, and HCV serum markers to avoid any flare-ups of viral hepatitis during chemotherapy. Antibodies to HIV 1 and 2 were sought using a commercial enzyme-linked immunosorbent assay (ELISA) (Abbott Lab., North Chicago, Ill, USA), with positive results always confirmed by Western blot analysis (Genelabs Diagnostics, Science Park Drive, Singapore); HBsAg, total anti-HBc, and anti-hepatitis B surface antibody (HBs),and anti-HCV were tested using commercial immunoenzymatic assays (Abbott Laboratories, North Chicago, IL, USA: AxSYM® HBsAg (v2) M/S for HBsAg, AxSYM® HCV (v3) for anti-HCV, AxSYM® CORE™ (v2) for total anti-HBc, and AxSYM® AUSAB® for anti-HBs) as described in previous studies [5][6][7][8][9]. The results were HIV-1,2 negative, HCV-Ab negative, HBsAg/HBsAb negative and HBcAb positive.…”
Section: Case Reportmentioning
confidence: 99%
“…The patient was affected by CLL stage II according to Rai with symptomatic active bulky disease and he needed treatment. The patient was also tested for serum markers of HIV, HBV, HCV, and CMV and was found positive only for anti-HBc, as a sign of previous HBV infection [26][27][28][29][30]. Lamivudine prophylaxis at the dose of 100 mg/day was administered 4 weeks before the start of chemotherapy, in order to prevent HBV reactivation.…”
Section: Case Reportmentioning
confidence: 99%
“…A sustained virological response and a lymphoproliferative disease response were obtained in 98% and 67%, respectively, of 45 patients with indolent B‐cell NHLs after completing a course of DAA therapy . Only few, but encouraging, studies have been published on DAA therapy in patients with B‐cell non‐Hodgkin lymphoma …”
Section: Impact Of Antiviral Hbv and Hcv Treatment On Development Of mentioning
confidence: 99%